Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Hydrolases (3. ) (e.g., urease, lipase, asparaginase, muramidase, etc.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424940100 - ENZYME OR COENZYME CONTAINING

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424940630 Acting on peptide bonds (3.4) (e.g., urokinease, etc.) 445
424940610 Acting on glycosyl compound (3.2) (e.g., glycosidases lysozyme, nucleosidases, cellulase, etc.) 176
Entries
DocumentTitleDate
20090123450PHARMACEUTICAL PREPARATION AND METHOD OF TREATMENT OF HUMAN MALIGNANCIES WITH ARGININE DEPRIVATION - The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.05-14-2009
20080260715Precursor N-acetylgalactosamine-4 sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme - The present invention provides a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant precursor enzyme to a highly purified form.10-23-2008
20110195060PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydroiase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.08-11-2011
20090169536Polypeptide Having Phytase Activity and Nucleotide Sequence Encoding the Same - The invention relates to a recombinant DNA molecule, which, upon expression in a prokaryotic or eukaryotic host cell, encodes a polypeptide having phytase activity, wherein the recombinant DNA molecule comprises a DNA sequence selected from a) DNA sequences that have been obtained by variations of the mature wild-type 07-02-2009
20100158888USE OF ALKALINE PHOSPHATASE TO MAINTAIN HEALTHY TISSUE MASS IN MAMMALS - Embodiments of the present invention relate to the use of placental alkaline phosphatase, and other members of the alkaline phosphatase family, to enhance protein synthesis in the muscle as well as the survival of non-cancerous differentiated cells in the muscle, adipose and other tissues. The ability of alkaline phosphatase to selectively enhance the survival of healthy cells and increase protein synthesis has many therapeutic applications. The use of alkaline phosphatase may prevent the loss of body weight and muscle mass typically experienced by diseased (such as cancer) or aging patients, or developing fetuses subjected to harmful conditions, or by patients who are treated with a toxic therapy including chemotherapy.06-24-2010
20090263370METHODS FOR TREATING TACHYKININ-MEDIATED DISEASES WITH CHOLINESTERASE - Methods for treating or preventing a tachykinin-mediated disease, a skin disorder, or a symptom thereof in a mammal by administering to a mammal in need thereof cholinesterase or a pharmaceutical composition of cholinesterase.10-22-2009
20090311234USE OF BETA-LACTAMASE - Class A beta-lactamase may be used for reducing side-effects in the intestine associated with antibiotic therapy with a combination of beta-lactam antibiotic and beta-lactamase inhibitor.12-17-2009
20100074882METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS - Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a neuroprotective agent, for example, a substance capable of suppressing endogenous calcineurin or constitutively active calcineurin, inhibiting cleavage of calcineurin to constitutively active calcineurin, and/or directly or indirectly antagonizing calcineurin or constitutively active calcineurin (and combinations thereof), to a mammal having an eye with retinal detachment. The neuroprotective agent maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment.03-25-2010
20100074881MULTIPLE NEBULIZER SYSTEMS - A device for administering two or more therapeutic agents simultaneously, comprising two or more nebulizers and a single connector linking the nebulizers to a nebulizer mouthpiece. Also provided is a method of administering two or more therapeutic agents simultaneously, comprising administering the therapeutic agents simultaneously with the device of the present invention to a subject in need thereof.03-25-2010
20130078229METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.03-28-2013
20120183524MOLECULAR TARGETS FOR TREATMENT OF INFLAMMATION - Molecular targets and methods for treating inflammatory disorders are described. The expression and/or functionality of molecular targets RelB or SIRT1 is modified in order to treat inflammatory disorders. The expression of RelB or SIRT1 may be increased, or the activity of RelB or SIRT1 may be increased in order to inhibit transcription factors which activate genes involved in inflammation. Inflammatory disorders such as chronic obstructive pulmonary disorder, rheumatoid arthritis, asthma and idiopathic pulmonary fibrosis are indicated.07-19-2012
20130084276BIOMARKERS OF CARDIOVASCULAR DISEASE INCLUDING LRG - The invention relates to differentially expressed disease - associated proteins that have potential to identify patients with cardiovascular disease including ventricular dysfunction and heart failure and the potential to predict heart failure in patients. In particular, the invention relates to the use of a panel of biomarkers in the diagnostic and prognostic evaluation of cardiovascular patients. One of the markers is Leucine-rich alpha-2-glycoprotein (LRG).04-04-2013
20130034534METHOD FOR TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS - A method for treatment of patients with cystic fibrosis by providing an inhalable aerosol comprising a mucolytic compound (dornase alpha) administered into a patient's lungs according to a specific treatment protocol setting comprising a mucolytic drug containing aerosol having particles with a predetermined mass medial aerodynamic diameter (MMAD) delivered predominantly to a peripheral lungs using a nebulizing system able to administer said aerosol with overpressure and under controlled breathing conditions.02-07-2013
20100068195Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof - This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.03-18-2010
20130078231DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINOGMYELINASE DEFICIENCY - The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.03-28-2013
20130078230DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINOGMYELINASE DEFICIENCY - The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.03-28-2013
20130039900COMPOSITIONS AND METHODS FOR ALTERING COCAINE ESTERASE ACTIVITY - The present invention relates to compositions and methods for treating and preventing cocaine addiction. In particular, the present invention provides mutated cocaine esterase proteins for use in treating and preventing cocaine addiction.02-14-2013
20100111924Chromosomal Modification Involving the Induction of Double-Stranded DNA Cleavage and Homologous Recombination at the Cleavage Site - Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.05-06-2010
20090155237COMPOSITIONS AND METHODS FOR BONE STRENGTHENING - The invention relates to methods of increasing bone strength in an animal, preferably a mammal. In one aspect, the methods provided by the invention involve administering to the animal strontium and a phytase enzyme. In another aspect, methods are provided for treating or preventing osteoporosis in a subject, the method comprising administering to said individual a phytase enzyme and strontium. Also encompassed are animal feed compositions comprising a phytase enzyme and supplemental strontium and a dietary supplement composition for administration to a human, the composition comprising a phytase enzyme and supplemental strontium.06-18-2009
20120164125NUCLEIC ACID CLEAVING AGENT - A nucleic acid cleaving agent having a cleaving activity specific to a desired cleavage site in a nucleic acid such as large DNA, which comprises (1) a nucleic acid cleaving moiety, and (2) at least two zinc finger proteins bound to the nucleic acid cleaving moiety, wherein at least one of the zinc finger proteins can specifically bind to a nucleotide sequence located upstream from the target cleavage site, and at least one of the remaining zinc finger proteins can specifically bind to a nucleotide sequence located downstream from the target cleavage site.06-28-2012
20120164124PHAGE-ASSOCIATED LYTIC ENZYMES FOR TREATMENT OF BACILLUS ANTHRACIS AND RELATED CONDITIONS - The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment of 06-28-2012
20090220478Pharmaceutical active substance - Pharmaceutical active substance for treating tumors in the area of breast tissue (breast carcinoma) while using peptide toxin, a substance that acts in an antagonistic manner thereto, and/or a penetrating substance extracted from the venom of spiders of the family Lycosa tarantula.09-03-2009
20130028881DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER SULFATASE DEFICIENCIES - This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.01-31-2013
20130028880APYRASE THERAPY FOR BLEEDING CONDITIONS - This invention provides new methods of treating subjects experiencing or at risk of bleeding due to vascular injury, especially to the microvasculature and/or platelet desensitization. Examples of injury usefully treated by apyrase agents are patho-physiological conditions, ischemia reperfusion injury, injury from pharmacologic agents such as anticoagulants, antiplatelet agents, antithrombotics, thrombolytics, and/or immunosuppressants, and injury resulting from transplantation. Apyrase agents are also useful to maintain organ function when said organs are transplanted into an allogeneic recipient.01-31-2013
20090304667Method of Regulating Mammalian Target-of-Rapamycin Activity by Interaction Between Phospholipase D and RHEB - The present invention relates to method of regulating mammalian target-of-rapamycin (mTOR) based on a novel finding of a regulating mechanism of mTOR by a phospholipase D (PLD), and Ras homolog enriched in brain (Rheb). Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibitin mTOR.12-10-2009
20130071373METHODS FOR THE DIAGNOSIS AND THERAPY OF RETINITIS PIGMENTOSA - The present invention relates to a method of identifying a subject having or at risk of having or developing a retinitis pigmentosa, comprising detecting in a sample obtained from said subject, the presence of at least one mutation in the rhodopsin (RHO) gene selected from the group consisting of c.263T>C, c.620T>A and c. 1031A>C wherein the presence of said mutation indicates an increased risk of having or being at risk of having or developing the retinitis pigmentosa.03-21-2013
20110038846PHARMACEUTICAL COMPOSITION, USE OF THE PHARMACEUTICAL COMPOSITION FOR TREATING A BRAIN TUMOR, PRODUCTION PROCESS THEREOF AND A KIT OF PARTS COMPRISING THE PHARMACEUTICAL COMPOSITION - The invention relates to the pharmaceutical composition for the treatment of a brain tumor, which contains in an effective amount from pharmaceutical point of view Peptidtoxin from spiders, 02-17-2011
20110014177Methods for Enhancing Physical and Mental Energy - A composition that includes thiamine disulfide diisobutyrate and caffeine. Related methods also are provided.01-20-2011
20090297495HYDROLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR IMPROVING PAPER STRENGTH - The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis of peptide bonds). In another aspect, the invention provides methods for hydrolyzing steryl esters and triglycerides (e.g., in a paper pulp), into sterols, glycerol and free fatty acids, using enzyme(s) of the invention. The invention provides enzymes and methods for decreasing the amount of lipophilic extracts (“pitch”) in a pulp-comprising composition. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts, including the manufacture of cosmetics and nutraceuticals.12-03-2009
20090269326Compositions of and methods of using sulfatases from flavobacterium heparinum - This invention is related, in part, to sulfatase enzymes and methods of their use.10-29-2009
20130064804BIO-REPLENISHMENT (BioRep) FOR IMPROVING SLEEP ARCHITECTURE - Methods to prepare a bio-replenishment (BioRep) with specific combinations of S-adenosylmethionine (SAMe), lactoferrin (LF) and ribonuclease (RNAse) to restore regular sleep pattern are described. Additionally, compositions of functional delivery systems that recreate both alternate phases of non-rapid eye movement (NREM) and rapid eye movement (REM) sleep cycles are disclosed. These methods and compositions have implications in the clinical management of various sleep disorders including insomnia, circadian rhythm disorders and obstructive sleep apnea.03-14-2013
20130064803BIO-REPLENISHMENT (BioRep) FOR COGNITIVE HEALTH - Methods to prepare a bio-replenishment (BioRep) with specific combinations of S-adenosylmethionine (SAMe), lactoferrin (LF) and ribonuclease (RNAse) to restore cognitive health are disclosed. These methods have implications in the clinical management of cognitive afflictions such as anxiety, dementia and depression.03-14-2013
20090238814COMPOSITIONS AND METHODS FOR TREATING HYPOPHOSPHATASIA - The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP which they produced by deleting the GPI anchor single peptide sequence. They have further shown that this composition is useful for treatment of hypophosphatasia. The inventors also disclose oligo acid amino acid variants thereof which specifically target bone tissue.09-24-2009
20090238813Compositions And Methods For Engineered Human Arginine Deiminases - The present invention discloses the engineering of a human enzyme with arginine hydrolytic activity suitable for human therapy. An enzyme comprising of a human sequence is not likely to induce adverse immunological responses and thus is expected to constitute a superior therapeutic. Since the human genome does not encode arginases with the proper high affinity catalytic properties (i.e., for example, a low Km and high catalytic activity, kcat) an appropriate arginase can be engineered by modifying an enzyme with related catalytic activity. For example, the human enzyme PAD4 can hydrolyze arginine in peptide substrates but does not have activity for free arginine. First, a high throughput assay was developed for detecting arginine activity by monitoring the formation of the hydrolytic product citrulline. Then, using a combination of rational design and iterative mutation and screening PAD4 mutants were identified and isolated exhibiting high affinity free arginine metabolic activity. These mutants did not retain activity for their original substrate, peptidyl arginine.09-24-2009
20090047271STABLE RECOMBINANT ADENOSINE DEAMINASE - A mutein recombinant adenosine deaminase having any oxidizable cysteine residue replaced by a non-oxidizable amino acid residue is disclosed. Stabilized recombinant adenosine deaminase, polymer conjugates and methods of treatment using the same are also disclosed.02-19-2009
20090047270ENZYMATIC ANTICANCER THERAPY - What is provided is a method of treating a patient having a tumor comprising administering an effective amount of adenosine deaminase, preferably polyalkylene oxide conjugated, to a patient in need thereof.02-19-2009
20090010912Use of Alkaline Phosphatase for the Detoxification of Lps Present at Mucosal Barriers - The present invention provides a use for alkaline phosphatase for the manufacture of a medicament for the prevention or reduction of toxic LPS influx through a mucosal lining of a mammalian body cavity. A source of alkaline phosphatase is administered for the prophylaxis or treatment of LPS mediated or exacerbated diseases. The invention also provides compositions comprising a source of alkaline phosphatase for the prevention or reduction of (toxic) LPS influx or passage through mucosal layers.01-08-2009
20100086535STABILIZATION OF PERHYDROLASES - Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided.04-08-2010
20130183284Method for Treating Systemic Bacterial, Fungal and Protozoan Infection - The invention is directed to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method comprises introducing a DNase enzyme into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa, wherein said DNase enzyme destroys extracellular DNA in said blood of said patient, said DNase enzyme being administered in doses and regimens which are sufficient to decrease the average molecular weight of circulating extracellular blood DNA in the blood of said patient.07-18-2013
20120237493NUCLEIC ACIDS ENCODING A MUT-T DOMAIN-CONTAINING POLYPEPTIDE - The invention pertains to nucleic acids encoding a mutT domain-containing polypeptide, including fragments and biologically functional variants thereof. The invention also pertains to therapeutics and diagnostics involving the foregoing polypeptide and nucleic acids and agents that bind the foregoing polypeptide and nucleic acids. The invention also pertains to the identification of a novel mutT domain in human TrpC7, a polypeptide previously described as a putative calcium ion channel. Accordingly, the invention also pertains to methods and compositions for identifying agents useful in modulating mutT domain-mediated calcium or other ion transport in cells expressing a polypeptide comprising a mutT domain and a calcium or other ion channel.09-20-2012
20120237492TREATMENT OF SUBMENTAL FAT - This disclosure relates to compositions, kits and methods for non-surgical reduction of localized subcutaneous fat such as that associated with a cosmetic fat accumulation. The methods employ compositions having specific concentrations of a salt of deoxycholic acid which provides a superior fat cell necrosis with modest adverse effects. Examples of localized subcutaneous fat are found in the submental area, in particular under the chin.09-20-2012
20100203032ORLISTAT COMPOSITIONS - A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.08-12-2010
20090311233MATERIALS AND METHODS DIRECTED TO ASPARAGINE SYNTHETASE AND ASPARAGINASE THERAPIES - Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies.12-17-2009
20100266569PROSTATIC ACID PHOSPHATASE FOR THE TREATMENT OF PAIN - Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord.10-21-2010
20090297496Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases - The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome,12-03-2009
20100266570DIMERIC DERIVATIVES OF ARTEMISININ AND APPLICATION IN ANTICANCER THERAPY - The present invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin of formula (I): or a pharmaceutically acceptable salt thereof with B10-21-2010
20120087904Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer - The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.04-12-2012
20100008896Use of Fenretinide or Bioactive Derivatives Thereof and Pharmaceutical Compositions Comprising the Same - The present invention relates to a new medical use of fenretinide or bioactive derivatives thereof, particularly to the use of fenretinide or bioactive derivatives thereof in the preparation of a medicament for eliminating or killing tumor stem cells in a subject or for treating and/or preventing a tumor disease originating from tumor stem cells in a subject. The invention further relates to a new use of fenretinide or bioactive derivatives thereof in combination with other anti-tumor agents, a pharmaceutical composition comprising said fenretinide or bioactive derivatives thereof and at least one additional anti-tumor agent, a method of screening said other anti-tumor agent, a method of eliminating or killing tumor stem cells or particularly hematologic tumor stem cells in a subject by administrating said fenretinide or bioactive derivatives thereof, as well as a method of eliminating or killing tumor stem cells and tumor cells derived from tumor stem cells, particularly hematologic tumor stem cells and hematologic tumor cells derived from hematologic tumor stem cells in a subject by administrating said fenretinide or bioactive derivatives thereof in combination with other anti-tumor agent(s).01-14-2010
20090202513RIBONUCLEASE AND THIAZOLIDINEDIONE COMPOUNDS AND THEIR USE IN METHODS TO TREAT CANCER - The present invention relates to methods and kits for the treatment of cancer. A novel drug combination comprising a ribonuclease compound and a thiazolidinedione compound has been identified as producing a synergistic cytotoxicity effect in cancer cells. Methods and kits pertaining to the co-administration of these compounds are discussed herein.08-13-2009
20110286993USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY - The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.11-24-2011
20090162339GALENIC FORMULATION FOR COLON-TARGETED DELIVERY OF ACTIVE INGREDIENTS - The invention concerns multiparticulate galenic formulations for oral administration and designed for colon targeted delivery of active principles selected from the group comprising enzymes capable of inactivating macrolides and the like, enzymes capable of inactivating quinolones and β-lactamases.06-25-2009
20110293596DISEASE CONTROL WITH TICK PHOSPHOLIPASE A2 - The present invention relates to reagents and methods for the modulation of viability of bacteria. A process is provided wherein a protein sequence from 12-01-2011
20110293595Prophylactic and therapeutic treatment of Alzheimer's Disease, neuro-degenerative diseases, protein aggregation diseases, Parkinson's Disease and amyloid diseases, using phytic acid and phytate - A composition and method for the treatment of Alzheimer's Disease, and/or related protein aggregation diseases and/or amyloidoses and/or a neuro-degenerative disease, and/or Parkinson's Disease and/or Parkinsonism including an effective amount of a compound selected from the group consisting of phytic acid (inositol hexakisphosphate), a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams at least once a week up to once per day, with or without a dephosphorylating enzyme. The dosage may be proportionately or disproportionately divided so that the dosage is administered in proportionally or disproportionately reduced amounts which cumulatively add up to a predetermined dosage, in a time period where the proportionately or disproportionately divided dosages are cumulatively equivalent in quantity to the dosage.12-01-2011
20090148431MODULATING THE PRODUCTION OF NEURONS AND/OR OLIGODENDROCYTES FROM WHITE MATTER PROGENITOR CELLS - The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and/or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes.06-11-2009
20110189156Method for Treating Systemic Bacterial, Fungal and Protozoan Infection - A treatment for the diseases that are accompanied by quantitative and qualitative changes of blood extracellular DNA and, more particularly, to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method consist from introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa when said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNASE enzyme: said agent must be administered in doses and regimens which sufficient to decrease number average molecular weight of circulating extracellular blood DNA in the blood of said patient; such decrease of number average molecular weight might be measured by gel electrophoresis of extracellular blood DNA fraction from the blood of said patient. A DNASE enzyme may be further applied in a dose and regime that provide a DNA hydrolytic activity measured in blood plasma exceeding 1.5 Kunitz units per 1 ml of blood plasma for more than 12 hours within a period of 24 hours.08-04-2011
20090041744Dimeric and Multimeric FVIIa Compounds - The present invention relates to dimeric or multimeric FVIIa compounds comprising at least two FVIIa polypeptides covalently connected such as to retain the intrinsic catalytic activity of the FVIIa polypeptides.02-12-2009
20110217281METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER - A method for diagnosing an early stage melanoma which includes detecting the expression level of dual specificity phosphatase 1 protein (DUSP1) and a method for determining a prognosis for a subject having melanoma which includes detecting the expression level of DUSP1 are disclosed. Also disclosed are pharmaceutical compositions and kits comprised by these methods.09-08-2011
20090162336Novel Tools for the Diagnosis and Treatment of Alzheimer's Disease - The invention relates to epitopes of the tau protein which are specifically occurring in a phosphorylated state in tau protein from Alzheimer paired helical filaments, to protein kinases which are responsible for the phosphorylation of the amino acids of the tau protein giving rise to said epitopes, and to antibodies specific for said epitopes. The invention further relates to pharmaceutical compositions for the treatment or prevention of Alzheimer's disease, to diagnostic compositions and methods for the detection of Alzheimer's disease and to the use of said epitopes for the generation of antibodies specifically detecting Alzheimer tau protein. Additionally, the invention relates to methods for testing drugs effective in dissolving Alzheimer paired helical filaments or preventing the formation thereof.06-25-2009
20090130080PLACENTAL ALKALINE PHOSPHATASE TO CONTROL DIABETES - The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.05-21-2009
20100111925Compositions of Engineered Human Arginases and Methods for Treating Cancer - Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.05-06-2010
20100111923USE OF ALKALINE PHOSPHATASE IN THE TREATMENT OF REDUCED RENAL FUNCTION - The invention relates to the field of medicine and in particular to the use of alkaline phosphatase in the treatment of renal diseases, such as reduced renal function. The present invention also relates to the field of pharmacy and in particular to the pharmaceutical use of alkaline phosphatase. The present invention provides an alternative treatment to improve a situation in which the renal function is reduced by using alkaline phosphatase.05-06-2010
20090148430HUMAN OBESITY SUSCEPTIBILTY GENE ENCODING POTASSIUM ION CHANNELS AND USES THEREOF - The present invention more particularly discloses the identification of human obesity susceptibility genes, which can be used for the diagnosis, prevention and treatment of obesity ant associated disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses certain alleles of potassium voltage-gated channel (E.CNA) genes related to susceptibility to obesity and representing novel targets for therapeutic intervention. More particularly, the potassium volt-age-gated channel (KCNA) genes are located on chromosome 12 and are selected from the group consisting of KCNA1, KCNA5 and KCNA6. The present invention relates to particular mutations in the KCNA1, KCNA5 and KCNA6 genes and their expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of coronary heart disease and metabolic disorders, including but not limited to hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and associated complications and dyslipidemia.06-11-2009
20090148429DEBRIDING COMPOSITION FROM BROMELAIN AND METHODS OF PRODUCTION THEREOF - The present invention relates to a debriding composition obtained from bromelain and to methods of producing same. Particularly, the present invention relates to a debriding composition obtained from bromelain comprising proteolytic enzymes having molecular weights of about 23 kDa, being essentially devoid of bromelain inhibitors, and to pharmaceutical compositions comprising same. The debriding compositions and the pharmaceutical compositions comprising same are particularly useful in debriding eschar tissues and in wound healing.06-11-2009
20090004173Diagnosis and Treatment of Drug Resistant Leukemia - The present invention encompasses methods and compositions useful in the diagnosis and treatment of drug resistant leukemia. The invention provides a number of genes that are differentially expressed between drug resistant and drug sensitive acute lymphoblastic leukemia (ALL). These genes act as biomarkers for drug resistant leukemia, and further serve as molecular targets for drugs useful in treating drug resistant leukemia. Accordingly, the invention provides methods of diagnosing drug resistant leukemia and methods of selecting a therapy for subjects affected by drug-resistant leukemia. The invention also provides methods for screening for compounds for treating drug-resistant leukemia, and improved methods for treating drug-resistant leukemia. Compositions of the invention include arrays, computer readable media, and kits for use in the methods of the invention.01-01-2009
20080241121INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY AS ADJUNCTS TO OPIATES FOR PAIN - A method for treating opiate induced tolerance or opiate induced hyperalgesia in a subject is closed. More specifically, the method provides for reducing ceramide levels with an agent thereby treating opiate induced antinociceptive/analgesic tolerance or hyperalgesia in a human or non-human subject. The method further allows for improved pain management in subjects suffering from chronic pain as well as treatment for opiate induced disorders.10-02-2008
20090087422Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same - The present invention relates to pharmaceutical compositions for treating diseases and conditions caused by ischemia. The pharmaceutical compositions contain a conjugate of a phospholipase (PL) polypeptide and a protein transduction domain (PTD). PLC-δ plays a major role in the regulation of cytosolic calcium levels. During myocardial ischemia, cytosolic calcium accumulation mediates pathogenic changes. According to the present invention, ischemic diseases or conditions leading to hypoxia in tissues, such as the heart and the brain, can be prevented or alleviated by administration of a PTD-PL conjugate.04-02-2009
20120189606Antimicrobial Agents - The present invention relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The present invention also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said fusion protein.07-26-2012
20120189605MANUFACTURE OF ACTIVE HIGHLY PHOSPHORYLATED HUMAN N-ACETYLGALACTOSAMINE-6-SULFATASE AND USES THEREOF - This invention provides compositions of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase (GALNS), and pharmaceutical compositions and formulations thereof, methods of producing and purifying GALNS, and its use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the GALNS enzyme, e.g., Mucopolysaccharidosis IVa (MPS IVa or Morquio A syndrome).07-26-2012
20110110918ROLE OF (DE)ACETYLATION IN COUNTERACTING PROTEIN AGGREGATION - The invention provides a method for influencing an activity of a heat shock protein which is a member of the Hsp40/DnaJ family, the method comprising acetylating or deacetylating said heat shock protein.05-12-2011
20120107299PHOSPHORYLATION-INHIBITING AGENT OR DEPHOSPHORYLATING AGENT FOR PTEN - Provided is a preventive, progression inhibitor or remedy for a disease one of the causes of which is the activation of the P13K/AKT signaling pathway or vice versa. A phosphorylation-inhibiting and/or dephosphorylating agent, which has an effect of inhibiting the phosphorylation at least at one of the phosphorylation sites of PTEN protein selected from the group consisting of T382, T383 and S380 and/or an effect of dephosphorylating the same, is prepared. Alternatively, a phosphorylation-inhibiting or dephosphorylating agent for PTEN is screened by a method comprising a step for confirming an ability of a test substance to inhibit the phosphorylation at least at one of the phosphorylation sites of PTEN protein selected from the group consisting of T382, T383 and S380 or a dephosphorylation ability thereof. Then, a substance having an effect opposite to the inhibition of PTEN phosphorylation or dephosphorylation thereof, e.g., an antibody against the phosphorylation-inhibiting or dephosphorylating agent for PTEN obtained above, is also obtained.05-03-2012
20080206222Preventive/Therapeutic Composition For Free Radical Disease - A preventive/therapeutic composition for free radical diseases, characterized by containing as an active ingredient at least one kind of a fullerene, a fullerene derivative, and a composite comprising a fullerene or fullerene derivative and an organic compound with which the fullerene or derivative has been modified or clathrated. The composition is reduced in side effects, has the high ability to eliminate free radicals in the body, and further has excellent preparation stability.08-28-2008
20090274681NOVEL GENE ENCODING A DNA REPAIR ENZYME AND METHODS OF USE THEREOF - An isolated nucleic acid molecule encoding a human DNA repair enzyme, MED1, is disclosed. Like other mismatch repair genes which are mutated in certain cancers, MED1, encoding nucleic acids, proteins and antibodies thereto may be used to advantage in genetic or cancer screening assays. MED1, which recognizes and cleaves DNA, may also be used for the diagnostic detection of mutations and genetic variants.11-05-2009
20090274680Human Phospholipases - The invention provides human lipid metabolism enzymes (LME) and polynucleotides which identify and encode LME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LME.11-05-2009
20090274679PRODUCTION AND USE OF HUMAN BUTYRYLCHOLINESTERASE - The present invention concerns the production of human butyrylcholinesterase (BuChE) in transgenic plants and use of the derived BuChE as effective countermeasures against toxic agents such as pesticides, toxins, certain drugs and non-conventional warfare agents, as well as treatments for diseases and conditions associated with depressed cholinesterase levels.11-05-2009
20100278804Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders - The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.11-04-2010
20090041742HUMAN DNASE II - This invention relates to a novel human deoxyribonuclease, referred to as human DNase II. The invention provides nucleic acid sequences encoding human DNase II, thereby enabling the production of human DNase II by recombinant DNA methods in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and diagnostic and therapeutic uses of human DNase II.02-12-2009
20090041743SPERM-BLOCKING AGENT COMPOSITION WITH CONTRACEPTIVE EFFECT - A sperm-blocking agent is disclosed. The composition comprises an aqueous solvent a gum which is a polysaccharide having about 0.3 to 10 wt % of the composition, wherein the polysaccharide is selected from the group consisting of celluloses and their derivatives, hemi-cellulose, fiber, starches and their derivatives, polydextrans and their derivatives, pectins and their derivatives, seaweed polysaccharids, their salts and derivatives and natural gums; and a lubricant being alcohols having about 0.5 to wt % of the composition, wherein the alcohol is at least one selected from polyethene glycol having a molecular weight of over 200, polypropylene glycol having a molecular weight poly(ethylene oxide) polymers and glycerin; wherein the viscosity of the composition is above 9000 cst.02-12-2009
20100129341FUSION PROTEINS OF COLLAGEN-BINDING DOMAIN AND PARATHYROID HORMONE - Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.05-27-2010
20080274095Biocides - The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).11-06-2008
20090068164SEQUENCE ENABLED REASSEMBLY (SEER) - A NOVEL METHOD FOR VISUALIZING SPECIFIC DNA SEQUENCES - The present invention provides a nucleotide sequence detection system in which a reporter enzyme is split into two halves each half of which is associated with at least one zinc finger domain. Upon DNA binding to the specific sequence defined by the zinc finger domains associated with the respective halves, the split-protein reassembles to reconstitute a functional enzyme. As such, the present invention provides methods of using the nucleotide sequence detection system for various diagnostic and identification purposes.03-12-2009
20080292609Use of Arginase in Combination with 5FU and Other Compounds for Treatment of Human Malignancies - The present invention provides a method for treating cancer in a human patient by reducing the physiological arginine levels to below 10 μM in combination with administering an anti-neoplastic compound. The present invention also provides a pharmaceutical composition comprising an arginine reducing compound, such as pegylated human arginase I, and an anti-neoplastic compound, such as 11-27-2008
20110142817MEANS AND METHOD FOR TREATING AND/OR PREVENTING NECROTIZING ENTEROCOLITIS - Compositions comprising a source of alkaline phosphatase that prevent or reduce toxic influx of lipopolysaccharide (LPS) through mucosal layers of a mamalian body cavity and methods of using these compositions for those purposes are disclosed. Such a source of alkaline phosphatase, preferably in a medical food such as infant milk formula, is eaten, drunk or otherwise administered for prophylaxis or treatment of LPS-mediated or LPS-exacerbated disease.06-16-2011
20080219965Phytase Variants - The present invention relates to phytase variants, their preparation and uses, which phytase variants, when aligned according to FIG. 09-11-2008
20080233100TARGETED ENZYMES - The present invention provides targeted enzymes that bind to targets better than the corresponding pre-targeted enzymes bind the target under like conditions, methods of making targeted enzymes, methods of using targeted enzymes to treat diseases, and pharmaceutical compositions comprising targeted enzymes.09-25-2008
20080279843Method For Improving Insulin Sensitivity By Administering an Inhibitor of Antitrypsin - Methods of delaying the onset or treating the progression of Type 2 diabetes in subjects that have increased blood levels of an inflammation marker protein. In one embodiment, the method includes administering an inhibitor OF α11-13-2008
20090053192TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF - Disclosed herein are tissue-nonspecific alkaline phosphatase (TNAP) activators and uses thereof for promoting bone mineral deposition.02-26-2009
20090162338Compositions and Methods for Identifying Agents which Modulate PTEN Function and PI-3 Kinase Pathways - Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.06-25-2009
20090181004MODIFIED BETA-LACTAMASE AND METHOD FOR ITS PREPARATION - The invention relates to targeted post translational modifi-cation of metallo-beta-lactamase by truncation and inser-tion of a dipeptide at the amino terminal end to reduce amino terminal heterogeneity in a recombinant DNA pro-duction system. A protein K-T-E-ΔBL is expressed, and modified by host proteases to E-ΔBL. Appropriate nucleotide molecules, vectors and hosts are also de-scribed. E-ΔBL is useful in a pharmaceutical composition for treating antibiotic induced adverse effects in the intes-tine of patients treated with beta-lactam antibiotics.07-16-2009
20110206654Methods of Modulating Gastrointestinal Tract Flora Levels with Alkaline Phosphatase - This invention relates generally to a therapeutic use of alkaline phosphatase to modulate gastrointestinal tract flora levels in subject.08-25-2011
20110217282Novel Toxin-Antitoxin System - Disclosed in certain embodiments is a method of inhibiting cell function comprising inducing the expression of a mRNA interferase that cleaves mRNA at GCU.09-08-2011
20090130079INTRAVENTRICULAR ENZYME DELIVERY FOR LYSOSOMAL STORAGE DISEASES - Lysosomal storage diseases can be successfully treated using intraventricular delivery of the enzyme which is etiologically deficient in the disease. The administration can be performed slowly to achieve maximum effect. Surprisingly, effects are seen on both sides of the blood-brain barrier, making this an ideal delivery means for lysosomal storage diseases which affect both brain and visceral organs.05-21-2009
20080317731Phospholipases, Nucleic Acids Encoding Them and Methods for Making and Using Them - The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP)) and/or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.12-25-2008
20090252718Phospholipase(s) and Use(s) Thereof - The invention relates to phospholipase(s), isoforms, derivatives, mutants and/or fragments thereof, for the preparation of a medicament for the treatment and/or prevention of ischemia. Preferred is the use of secretory phospholipase, particularly phospholipase A10-08-2009
20130121984BIOMARKERS FOR SANFILIPPO SYNDROME AND USES THEREOF - The present invention provides biomarkers for efficient and accurate characterization of Sanfilippo syndrome. In particular, the present invention provides biomarkers differentially expressed in Sanfilippo syndrome. Those biomarkers, used alone or in combination, may permit more accurate robust characterization of Sanfilippo syndrome, resulting in more precise determination of the types and/or severity of the syndrome. In addition, inventive biomarkers according to the present invention can be used to effective monitor treatment response in Sanfilippo syndrome patients and/or to optimize treatment for Sanfilippo syndrome.05-16-2013
20130121986NITROGENATED DERIVATIVES OF PANCRATISTATIN - The present invention concerns nitrogenated derivatives of narciclasine and pancratistatin of the following general formula (I) as well as their pharmaceutically acceptable salts. The present invention also concerns the use of these compounds in cancer therapy as well as a method for their preparation.05-16-2013
20130216516METHOD FOR TREATING DELAYED-TYPE HYPERSENSITIVITY - The invention is directed to treatment of delayed-type hypersensitivity reactions associated with changes of qualitative and/or quantitative composition of blood extracellular DNA and treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.08-22-2013
20090081183HIV Transcription Repressor Complex and Compositions and Methods Based Thereon - The molecular mechanism of YY1/LSF-associated repression of HIV-1 is described herein. More particularly, an HIV transcription repressor complex containing YY1, LSF and HDAC1 is described. The invention is based on our discovery that (1) HDAC1 co-purifies with the LTR-binding YY1-LSF repressor complex; (2) the domain of YY1 that interacts with HDAC1 is required to repress the HIV-1 promoter; (3) the expression of HDAC1 augments repression of the LTR by YY1, and (4) the deacetylase inhibitor trichostatin-A blocks repression mediated by YY1. This novel link between HDAC1 recruitment and inhibition of HIV-1 expression by YY1 and LSF, in the natural context of a viral promoter integrated into chromosomal DNA, supports novel HIV therapies described herein and has significant implications for the long-term treatment of AIDS.03-26-2009
20110142816THERMOSTABILIZATION OF PROTEINS - Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal under-going a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.06-16-2011
20080299106COMBINATIONS OF HUMAN PROTEINS TO ENHANCE IN VIVO VIABILITY OF STEM CELLS AND PROGENITOR CELLS - Embodiments of the present invention include the use of placental alkaline phosphatase and other members of the alkaline phosphatase family alone or in combination with human transferrin and, optionally, human α12-04-2008
20090053191PHOSPHOLIPASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.02-26-2009
20090098101COMPOSITIONS AND METHODS FOR RIBONUCLEASE-BASED THERAPEUTICS - The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).04-16-2009
20090208480LONG HALF-LIFE RECOMBINANT BUTYRYLCHOLINESTERASE - The present invention provides for butyrylcholinesterase (BChE) attached to polyethylene glycol (PEG) to form a complex having greatly increased mean residence time (MRT) in the system of an animal following injection thereinto. Also disclosed are compositions of such complexes, methods of preparing these complexes and method for using these complexes and compositions in the treatment and/or prevention of toxic effects of poisons, such as neurotoxins, to which said animals, such as humans, have been, or may become, exposed.08-20-2009
20090246187PROCESS FOR CONCENTRATION OF A POLYPEPTIDE - The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.10-01-2009
20100150898COMPOUNDS AND METHODS FOR THE TREATMENT OF AIRWAY DISEASES AND FOR THE DELIVERY OF AIRWAY DRUGS - Chronic obstructive airway diseases are treated by administering an osmotically active compound such as a salt, sugar, sugar alcohol, or organic osmolyte to the afflicted airway surface. The compound may be administered as a liquid or dry powder aerosol formulation. Diseases that can be treated by the method include cystic fibrosis, chronic bronchitis, and ciliary dyskinesia. The formulations of the invention can also be used in conjunction with other active agents such as bronchodilators, sodium channel blockers, antibiotics, enzymes, or purinoceptor agonists on airway surfaces.06-17-2010
20120195875DETECTION OF IMMUNE MODULATION RESULTING FROM REDUCED PROTEIN PHOSPHATASE 2A ACTIVITY - The inventors demonstrate herein that measuring the level of protein phosphatase 2A activity (PP2A) is useful for assessing immune modulation and susceptibility to infection in an individual. This invention is especially useful when applied to septic individuals, and individuals with chronic infections. The invention also teaches a method of prevention and treatment of secondary infections, as well as prevention and treatment of cancerous conditions.08-02-2012
20120195874DFPASE ENZYMES FROM APLYSIA CALIFORNICA - The present invention relates to isolated polypeptides having organophosphorous hydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.08-02-2012
20090317372SMALL MOLECULES FOR THE REDUCTION OF HIGH BLOOD GLUCOSE LEVEL - Embodiments of the present invention include the in vivo use of a family of heterocyclic compounds containing a quaternary ammonium group as exemplified by the thioxanthone and thioxanthene compounds [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride, or CCcompound1, N,N,-diethyl-N-methyl-2-[9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide, or CCcompound3, and N,N,N-trimethyl-3-(9H-thioxanthen-9-ylidene)-propane-1-aminium iodide, or CCcompound19 to reduce higher than normal blood glucose level within or close to the normal range in subjects with insulin resistance, hyperglycemia, and diabetes thereby also reducing or preventing associated diseases, complications, and pathological states.12-24-2009
20110229450ENZYMES AND METHODS FOR DEGRADING S-TRIAZINES AND DIAZINES - The present invention relates to polypeptides for degrading s-triazines such as atrazine, as well as diazines. Also provided are polynucleotides encoding these polypeptides. The present invention also relates to the use of these polynucleotides and polypeptides in the bioremediation of s-triazines and diazines.09-22-2011
20100183580TREATMENT OF PIGS FOR REDUCING THE FEED CONVERSION RATIO OR INCREASING THE GROWTH RATE - The invention relates to a method for the non-therapeutic treatment of pigs for the purpose of reducing the conversion ratio of the feed used to raise the pigs and/or for increasing the growth rate of the pigs. The treatment comprises orally administering at least one glycine compound to the pigs, which glycine compound corresponds to the following formula (I) or to a salt or an ester thereof: wherein R07-22-2010
20100183581Compositions and Methods for Modulating Blood-Brain Barrier Transport - This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.07-22-2010
20100226907PURIFICATION OF BUTYRYLCHOLINESTERASE USING MEMBRANE ADSORPTION - The present invention relates to purification of butyrylcholinesterase using anion exchange material, where the butyrylcholinesterase content is enriched at least 10 fold per total protein in the composition.09-09-2010
20100239558Lipid Hydrolysis Therapy for Atherosclerosis and Related Diseases - The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.09-23-2010
20090017004POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID - The present invention provides polymeric delivery systems including an aromatic allyllic acyl group. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.01-15-2009
20100254965Adenosine Signaling in Diagnosis, Treatment, and Prevention of Priapism and Erectile Dysfunction - We disclose a method of treating priapism in a mammal by administering to the mammal a composition containing an effective amount of an inhibitor of adenosine signaling and a pharmaceutically-acceptable carrier, wherein the inhibitor of adenosine signaling has at least one activity selected from the group consisting of decreasing adenosine levels in the mammal, inhibiting adenosine receptor activity in the mammal, and inhibiting signaling pathways downstream of an adenosine receptor in the mammal. We also disclose a method of treating erectile dysfunction in a mammal by administering to the mammal a composition containing an effective amount of an activator of adenosine signaling and a pharmaceutically-acceptable carrier, wherein the activator of adenosine signaling has at least one activity selected from the group consisting of increasing adenosine levels in the mammal, increasing adenosine receptor activity in the mammal, and increasing activity in signaling pathways downstream of an adenosine receptor in the mammal. In addition, we disclose a method of diagnosing erectile dysfunction in a mammal by administering to the mammal a composition containing an effective amount of an activator of adenosine signaling and a pharmaceutically-acceptable carrier, wherein the activator of adenosine signaling has at least one activity selected from the group consisting of increasing adenosine levels in the mammal, increasing adenosine receptor activity in the mammal, and increasing activity in signaling pathways downstream of an adenosine receptor in the mammal, and observing blood flow in the mammal's penis.10-07-2010
20090202512PROTEINS FOR USE IN HUMAN AND ANIMAL STAPHYLOCOCCUS INFECTIONS - The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO:08-13-2009
20100080789THERAPEUTIC RIBONUCLEASES - The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.04-01-2010
20120034204FERTILIZATION MODULATION COMPOUNDS AND PROCESS FOR IMPLEMENTING THEM - This invention relates to fertilization modulation compounds and process for implementing them.02-09-2012
20090186011Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof - This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.07-23-2009
20100303794Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions.12-02-2010
20110123516NITROGENATED DERIVATIVES OF PANCRATISTATIN - The present invention concerns nitrogenated derivatives of narciclasine and pancratistatin of the following general formula (I) as well their pharmaceutically acceptable salts. The present invention also concerns the use of these compounds in cancer therapy as well as a method for their preparation.05-26-2011
20110123513ALKALINE PHOSPHATASE TO REDUCE OR PREVENT WEIGHT GAIN - The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.05-26-2011
20100303795MARKER OF PROSTATE CANCER - An SLC18A2 gene serves as a marker of prostate cancer. Methods are provided for diagnosing prostate cancer, predicting or prognosticating the disease outcome, predicting recurrence following surgery, and monitoring disease progression in an individual having prostate cancer. The methods relate to determining the methylation state of an SLC18A2 gene and/or determining the level of transcription or translation of the gene in a sample from the individual. Methods of treating prostate cancer are also provided. The invention also pertains to compositions and kits for use in the methods.12-02-2010
20100303796Method for Treating Systemic DNA Mutation Disease - A treatment for systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA and, more particularly, to a treatment of diabetes mellitus and atherosclerosis. The inventive method consist from introducing a treatment agent into a circulating blood system of a patient diagnosed with systemic DNA mutation diseases when said treatment agent destroys extracellular DNA in said blood of said patient and wherein said treatment agent used to destroy said extracellular DNA is a DNASE enzyme: said agent might be administered in doses and regimens which sufficient to decrease number average molecular weight of circulating extracellular blood DNA in the blood of said patient;12-02-2010
20100303793COMBINATION THERAPY FOR CARDIAC REVASCULARIZATION AND CARDIAC REPAIR - An agonist of the non-proteolytically activated thrombin receptor and an angiogenic growth factor can be used in combination in methods of therapy to stimulate cardiac revascularization, to stimulate vascular endothelial cell proliferation, to stimulate vascular endothelial cell migration and to promote repair of cardiac tissue.12-02-2010
20130136727Angiogenin and Variants Thereof for Treatment of Neurodegenerative Diseases - Methods and compositions for treating neurodegenerative disorders using angiogenin and/or angiogenin variants are provided.05-30-2013
20130136728ANTI-COCAINE COMPOSITIONS AND TREATMENT - Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.05-30-2013
20090214510Broad Spectrum Antiviral Compositions - The instant invention provides compositions and methods for the treatment of viral infections caused by enveloped viruses comprising phospholipase nucleic acid molecules or polypeptides, or fusion molecules comprising phospholipase molecules or functional fragments thereof.08-27-2009
20130142775THERAPEUTIC APYRASE CONSTRUCTS, APYRASE AGENTS, AND PRODUCTION METHODS - This invention provides a new class of enhanced apyrases (EN-apyrases) with superior pharmacokinetic, pharmacodynamic, and pharmacochemical properties and which can be purified using simplified procedures. The invention further provides constructs for transforming a cell to produce these EN-apyrases. The EN-apyrase construct comprises sequences encoding a signal sequence, a linker, and a soluble apyrase. Also provided are preparations of apyrases and methods for producing apyrase in culture cells and purification thereof.06-06-2013
20090068166METHOD AND COMPOSITION FOR PROTECTION AGAINST RADIATION - Methods are described for using an arginine depleting agent such as arginase and derivatives thereof, which reduce physiological arginine levels, as radioprotectants to protect normal mammalian cells from DNA damage caused by ionizing radiation. Treatment can result in the protection of normal tissues in cancer patients undergoing radiotherapy and in protection from the hazardous effects of exposure to radiological dispersal devices or occupational and environmental ionizing radiation.03-12-2009
20110033438Method and pharmacological composition for the diagnosis and treatment of male - Pharmaceutical compositions for treating male sub-fertility that include an agent that causes a reduction in an effect of extracellular DNA on sperm cells, are provided. The agent may be, for example, an enzyme that degrades DNA such as DNase, a substance that blocks the interaction between cell free DNA and sperm cell surface receptors, a substance that binds to DNA, a substance that inhibits endogenous sperm cell DNase, a substance that inhibits a member of a signal transduction pathway mediated by DNA binding to sperm cell surface receptors, or an agent that stimulates production of an endogenous substance that causes a reduction in an antifertility effect of cell free DNA on sperm cells. Also provided are methods for treating male sub-fertility by administering the pharmaceutical composition to a subject in need thereof. Further provided are methods for determining a fertility status in a male subject, methods for assisted reproduction, methods for selecting an assisted reproduction technique (ART), and methods for selecting sperm cells in a sperm cell population for use in an assisted reproduction technique.02-10-2011
20090220479EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASE - The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.09-03-2009
20100143323MODIFIED PHOSPHATASES - The invention relates to phosphatases and more in specific to (genetically) modified phosphatases, pharmaceutical compositions comprising (genetically) modified phosphatases and the use of (genetically) modified phosphatases for treating or curing for example sepsis, inflammatory bowel disease or other inflammatory diseases, or renal failure. The invention further relates to a method for producing phosphatases.06-10-2010
20110243915ANTIMICROBIAL AGENTS - The present invention relates to endolysin variants comprising an endolysin to which a peptide stretch with membrane or LPS disrupting activity is fused. Moreover, the present invention relates to nucleic acid molecules encoding said modified endolysin variant, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to a method for producing said endolysin variant. Further, the present invention relates to said modified endolysin variant for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said endolysin variant as a diagnostic means in medicinal, food or feed or environmental diagnostic. Finally, the present invention relates to a pharmaceutical composition comprising said modified endolysin variant10-06-2011
20110250192USE OF MICRORNA SIGNATURES FOR ASSESSING RISK LEVELS OF NEUROBLASTOMA PATIENTS - Methods for assessing the risk level or survival/death probability of a neuroblastoma patient based on a number of microRNA signatures, optionally in combination with Dicer, Drosha, and age at diagnosis. Also disclosed herein is use of Dicer, Drosha, or both in suppressing neuroblastoma cell growth10-13-2011
20100055085HYDROLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - Provided are hydrolases, including lipases, saturases, palmitases and/or stearatases, and polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. Further provided are polypeptides, e.g., enzymes, having a hydrolase activity, e.g., lipases, saturases, palmitases and/or stearatases and methods for preparing low saturate or low trans fat oils, such as low saturate or low trans fat animal or vegetable oils, e.g., soy or canola oils.03-04-2010
20100034800COMPOSITIONS FOR DETECTING CELL DEATH AND METHODS OF USE THEREOF - The invention provides compounds and methods of their use in the detection of apoptosis and necrosis both in vitro and in vivo. Also provided are compounds and methods of their use in selective delivery of agents to cells undergoing apoptosis or necrosis. The compounds and methods are based on conjugates formed with a dehydrogenase such as lactate dehydrogenase, alcohol dehydrogenase, aldehyde dehydrogenase, and malate dehydrogenase. The compounds and methods are useful in the diagnosis and treatment of conditions characterized by apoptosis, including cancer, cardiac disease, neurologic disease including stroke, and autoimmunity. The compounds and methods offer distinct advantages over corresponding compounds and methods based on Annexin V. Also provided are methods for screening for compounds that modulate, i.e., inhibit or promote, apoptosis.02-11-2010
20090035292Use of phosphatases to treat neuroblastomas and medulloblastomas - Disclosed herein are methods of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a phosphatase ligand in an amount effective to treat the subject. Also disclosed herein are method of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a histone deacteylase ligand in an amount effective to treat the subject.02-05-2009
20090035291THERAPEUTIC USE OF ADPASE ENHANCED APYRASES - The present invention provides for design and therapeutic use of ADPase enhanced polypeptides, pharmaceutical compositions, and methods useful for preventing and reversing platelet aggregation and recruitment for the treatment and prevention of vascular disorders in mammals.02-05-2009
20110177055COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS - The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase,07-21-2011
20090181005NUCLEIC ACID ENCODING PROTEINS INVOLVED IN PROTEIN DEGRADATION, PRODUCTS AND METHODS RELATED THERETO - In accordance with the present invention, there are provided novel Siah-Mediated-Degradation-Proteins (SMDPS) and/or SCF-Complex Proteins (SCPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SMDPs and/or SCPs can be employed in a variety of ways, for example, for the production of anti-SMDP and/or SCP antibodies thereto, in therapeutic compositions, and methods employing such proteins and/or antibodies for drug screening, functional genomics and other applications. Also provided are transgenic non-human mammals that express the invention protein. Also provided are compositions and methods for targeting the destruction of selected polypeptides in eukaryotic cells based on the ubiquitin-independent mechanism by which ornithine decarboxylase is degraded by the 26S proteasome.07-16-2009
20110081332TREATMENT OF NON-ALCOHOLIC STEATOTIC HEPATITIS (NASH) - The present invention relates to a method for treating non-alcoholic steatotic hepatitis (NASH) in a subject by administering an effective amount of a lipoprotein lipase (LPL) therapeutic to the subject. The LPL therapeutic is advantageously a S447X protein or a derivative or variant thereof, or a nucleic acid encoding such a protein. The LPL therapeutic may be used in a gene therapy vector.04-07-2011
20110150857PERHYDROLASE PROVIDING IMPROVED PERACID STABILITY - An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a 06-23-2011
20100086533LAGLIDADG HOMING ENDONUCLEASE VARIANTS HAVING NOVEL SUBSTRATE SPECIFICITY AND USE THEREOF - A LAGLIDADG homing endonuclease variant having novel substrate specificity, said variant being obtainable by a method comprising: (a) the mutation of at least one amino acid residue of the final C-terminal loop of a parent LAGLIDADG homing endonuclease, with the exclusion of the threonine 140 of I-CreI, b) the selection and/or screening of the variants from step (a) having a pattern of cleaved DNA targets that is different from that of the parent LAGLIDADG homing endonuclease.04-08-2010
20090324574Esterases and Related Nucleic Acids and Methods - The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phosphplipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis of peptide bonds). The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts, including the manufacture of cosmetics and nutraceuticals. In another aspect, the polypeptides of the invention are used to synthesize enantiomerically pure chiral products.12-31-2009
20090136476ARABINOFURANOSIDASES - The present invention relates to isolated polypeptides having alpha-L-arabinofuranosidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides.05-28-2009
20100278803Alzheimer's Disease Diagnosis Based on Mitogen-Activated Protein Kinase Phosphorylation - A method of diagnosing Alzheimer's disease in a patient comprises determining whether the phosphorylation level of an indicator protein in cells of the patient after stimulus with an activator compound is abnormally elevated as compared to a basal phosphorylation level, the indicator protein being e.g. Erk1/2 and the activator compound being e.g. bradykinin.11-04-2010
20110165141Compositions for treating bacterial infections - Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described.07-07-2011
20100284993Enhancing the Efficacy of Anti-Infective Therapeutics - In an embodiment of the invention, a method of enhancing the efficacy of an anti-infective therapeutic agent against an obligate or facultative intracellular parasite in a host is provided. The method comprises administering to the host an effective amount of a bifunctional compound of less than about 5000 Daltons comprising the therapeutic or an active derivative, fragment or analog thereof and a protein binding moiety. The protein binding moiety binds to at least one intracellular protein. The bifunctional compound has a higher intracellular concentration as compared to the therapeutic itself in order to enhance the efficacy of the anti-infective therapeutic against the obligate or facultative intracellular parasite.11-11-2010
20110135623Conjugates of a Cholinesterase Moiety and a Polymer - Conjugates of a cholinesterase moiety and one or more nonpeptidic, water soluble polymers are provided. Typically, the nonpeptidic, water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.06-09-2011
20110052560Method for Increasing the Activity of the Immune System of a Mammal at Risk of Inflammatory Diseases - The present invention relates to methods for increasing the activity of the immune system and, especially, to methods for increasing the activity of the immune system by modulation of endogenous ectophosphatase levels. According to a particularly preferred embodiment the present invention relates to methods for the prophylaxis of mammals, and especially human mammals, at risk of inflammatory diseases such as mammals suffering from conditions such as surgery, digestive tract diseases, respiratory diseases, skin diseases, burn wounds, smoke inhalation, intoxication, severe blood loss, food poisoning, chemotherapy, radiation therapy, severe trauma or liver diseases, immunocompromised conditions. For this, the present invention provides use of an ectophosphatase for the preparation of a medicament for the prophylaxis of a mammal at risk of inflammatory diseases.03-03-2011
20110052559DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY - The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.03-03-2011
20120148559COMPOSITIONS AND METHOD FOR DEIMMUNIZATION OF PROTEINS - The invention provides deimmunized mutant proteins having reduced immunogenicity while exhibiting substantially the same or greater biological activity as the proteins of interst from which they are derived, as exemplified by mutant L-asparaginase that comprises amino acid substitutions compared to wild type L-asparaginase. The invention further provides methods for screening mutant deimmunized proteins that have substantially the same or greater biological activity as a protein of interest, and methods for reducing immunogenicity, without substantially reducing biological activity, of a protein of interest.06-14-2012
20090110675USE OF PLATELET ACTIVATING FACTOR ACETYLHYDROLASE AS BIOMARKER FOR ANAPHYLAXIS - A method for determining a patient's susceptibility to anaphylaxis comprises assaying the activity of platelet activating factor acetylhydrolase (PAF-AH) activity and comparing the measured activity to a reference value, wherein the level of PAF-AH activity inversely correlates with the susceptibility to anaphylaxis. The method further comprises determining the severity of anaphylaxis by correlating the degree of reduced PAF-AH activity to the reference value. The method further comprises measuring IgE concentration and comparing the measured concentration to a reference concentration. The invention further provides a method for diagnosing anaphylaxis in a patient comprising measuring the serum concentration of platelet activating factor (PAF) and comparing the measured concentration to a reference value, wherein the concentration of PAF correlates directly with severity of anaphylaxis. The invention also provides a kit for performing the required assay or assays.04-30-2009
20110171197PON POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND COMPOSITIONS AND METHODS UTILIZING SAME - Isolated polynucleotides and polypeptides encoded therefrom are provided. These include mutated PON enzymes with increased, modified or substantially the same substrate specificity as compared to respective wild-type PON. Also provided are kits and methods using these enzymes.07-14-2011
20100028321DRUG TARGET FOR PREVENTING AND TREATING PERIODONTAL DISEASE, IMPROVING HEALING OF PERIODONTAL WOUNDS AND PROMOTING ORAL HEALTH - The present invention relates to the use of a component of the plasminogen-activating pathway and use of compounds which have the capacity to activate plasminogen directly or via the plasminogen-activating pathway, for prophylaxis, prevention and treatment of periodontal disease including peri-implantitis, healing of periodontal wounds and prompting oral health in human and non-human subjects.02-04-2010
20100021449ANGIOGENIN COMPLEXES (ANGex) AND USES THEREOF - Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by non-covalent immobilization on a naturally occurring substrate, such as a protein, lipid, nucleic acid or nucleotide substrate, are disclosed.01-28-2010
20100021448I-CREI MEGANUCLEASE VARIANTS WITH MODIFIED SPECIFICITY, METHOD OF PREPARATION AND USES THEREOF - Method of preparing 1-CreI meganuclease variants having a modified cleavage specificity, variants obtainable by said method and their applications either for cleaving new DNA target or for genetic engineering and genome engineering for non-therapeutic purposes. Nucleic acids encoding said variants, expression cassettes comprising said nucleic acids, vectors comprising said expression cassettes, cells or organisms, plants or animals except humans, transformed by said vectors.01-28-2010
20120308548METHIONINE GAMMA LYASE-2-AMINOBUTYRATE DEAMINASE (MEGL-2ABD) AND THERAPEUTIC USES THEREOF - The invention relates to a methionine gamma lyase-2-aminobutyrate deaminase (MEGL-2ABD) enzyme and provides an isotopic assay for quantitatively measuring activity of the enzyme. The MEGL-2ABD is a therapeutic target for cancer, particularly in cancer stem cells and their lineages. The invention additionally provides a protein, MEGL-2ABD (SEQ ID NO:2), compositions/formulations containing this protein, and methods/assays for using this protein in therapeutic applications allowing progress toward prevention, diagnosis, treatment, and cure of cancer.12-06-2012
20120148560NEUROPROTECTION FROM BRAIN ANOXIA AND REPERFUSION INJURY DURING STROKE AND COMPOSITIONS OF PKG PATHWAY ACTIVATORS AND METHOD OF USE THEREOF - A pharmaceutical composition for treating or preventing one or both of neural anoxia and reperfusion injury, which includes a pharmacological activator of the PKG pathway, and methods of treating or preventing medical conditions using a pharmacological activator of the PKG pathway.06-14-2012
20100189707Stable Enzymatic Peracid Generating Systems - The present invention provides stable compositions comprising a perhydrolase enzyme, a hydrogen peroxide source, and an ester substrate that efficiently generate aqueous peracid solutions. The generated peracid solutions are suitable for decontaminating and/or sanitizing a wide range of materials and equipment contaminated with pathogens or toxic chemicals. In one preferred embodiment, the stable composition comprises an acyl transferase enzyme, sodium percarbonate, and propylene glycol diacetate, and is stable for 30 days or longer. Upon addition to water, the composition is activated and generates an aqueous solution with a high ratio of peracetic acid to acetic acid.07-29-2010
20090232788Enzyme With Microbial Lysis Activity From Trichoderma Reesei - The invention provides fungal polypeptides from 09-17-2009
20110305683Stabilization Of Perhydrolases - Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided.12-15-2011
20100143324METHOD FOR TREATMENT OF CANCERS OR INFLAMMATORY DISEASES - The invention concerns a glycosylasparaginase polypeptide with L-asparaginase activity or its precursor for use in the treatment or prevention of cancers or inflammatory diseases. The invention concerns also a novel pharmaceutical composition comprising either i) the glycosylasparaginase polypeptide or its precursor, or ii) an expression vector encompassing a nucleic acid sequence encoding the glycosylasparaginase polypeptide or its precursor for use in the treatment or prevention of cancers or inflammatory diseases.06-10-2010
20110086015ZINC FINGER NUCLEASE FOR THE CFTR GENE AND METHODS OF USE THEREOF - The present invention provides new zinc finger proteins and zinc finger nuclease (ZFNs) that find particular using in repairing the cystic fibrosis transmembrane conductance regulator (CFTR) gene.04-14-2011
20090028842Dekkera/Brettanomyces Cytosine Deaminases And Their Use - The present invention relates to cytosine deaminase protein and cDNA from various species of the yeast genus 01-29-2009
20110008314METHODS OF AND COMPOSITIONS FOR INHIBITING THE PROLIFERATION OF MAMMALIAN CELLS - A method of preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The method is effected by administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family having actin binding activity.01-13-2011
20100178284Composition for the Skin, Specifically for Inhibiting Ingrown Hair - A crème for use in connection with the treatment and prevention of ingrown hair. The crème basically comprises a carrier, preferably water and an active amount of encapsulated bromelain, the encapsulated bromelain preferably comprising an inert silicone, preferably cyclomethicone. Other components can be added to the composition, for example, beeswax, sunflower seed oil, shea butter and/or Tea Tree oil. The crème can be used to treat acne, as well.07-15-2010
20090169537GLUTADON - The present invention relates to a pharmaceutical combination product for cancer therapy. The combination product comprises the two active ingredients glutaminase and 6-diazo-5-oxo-L-norleucine (DON). The invention further relates to the use of such a combination product for the treatment of cancers.07-02-2009
20090068165Uniformly Conjugated Serine Hydrolases - An organophosphate scavenger is provided, with extended residence time in the mammalian circulation, which can be used in preventive and therapeutic treatment of organophosphate poisoning. The scavenger is a uniformly pegylated serine hydrolase, in which a part of lysine residues were replaced with other residues by site-directed mutagenesis. One part of lysine residues in the hydrolase amino acid sequence is selected for the PEG-coupling, and the other part for the replacement, wherein the selection should ensure that the hydrolase surface shows at least one free amino acid for PEG coupling for all possible views obtained by rotating a 3-D model generated for the hydrolase.03-12-2009
20110064716MATERIALS AND METHODS FOR TREATING OR PREVENTING ORGANOPHOSPHATE EXPOSURE ASSOCIATED DAMAGE - A method of treating or preventing organophosphate exposure associated damage in a subject in need thereof is provided. The method comprising providing the subject with a therapeutically effective amount of AChE-R to thereby treat the organophosphate exposure associated damage in the subject.03-17-2011
20110064717Homing endonuclease genes and their targets - The invention provides pharmaceutical composition having as an active ingredient either a homing endonuclease (HE) capable of cleaving a non-native target nucleotide sequence in a genome or a nucleotide sequence encoding for a HE capable of cleaving a target site in a non-native genome. The invention also provides uses for such HEs, and methods of treatment utilizing such HEs. The HE may be, for example, any one of the HEs PI-SceI, POLB HE, PRP8 HE, or Nostoc species PCC7120 HE.03-17-2011
20120301456MEGANUCLEASE REAGENTS OF USES THEREOF FOR TREATING GENETIC DISEASES CAUSED BY FRAME SHIFT/NON SENSE MUTATIONS - The present invention relates to a method to treat a genetic disease in an individual caused by at least one frame shift or at least one non sense mutation in the human dystrophin gene comprising at least the step of bringing into contact at least one meganuclease enzyme, which recognizes and cuts a target site in the human dystrophin gene, with the genome of said individual under conditions wherein said at least one meganuclease recognizes and cleaves its target site in the human dystrophin gene. Said method applies also to a set of meganuclease enzymes, which each recognizes and cuts a different target site. The present invention also relates to a kit comprising, at least one meganuclease enzyme as defined above and medicament comprising said meganuclease.11-29-2012
20120009173CYTOTOXIC RIBONUCLEASE VARIANTS - This invention relates to cytotoxic variants of human ribonuclease 1 (RNase 1) identified through analysis of the interaction between RNase 1 and the human ribonuclease inhibitor (hRI) as defined by the three dimensional (3-D) atomic structure of the RNase1 hRI complex. Also disclosed is the 3-D structure of the hRI•RNase 1 complex and methods for designing the RNase 1 variants.01-12-2012
20100061971Method for Treating Human Diseases Associated With an Increased Deoxyribonucleic Acid Content in Extracellular Spaces of Tissues and a Medicinal Preparation for Carrying Out Said Method - The invention relates to medicine. The inventive method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and organs, consists in orally injecting a DNA ferment in a quantity of 20 000-500 000 Kunz units in a day per 1 kg of the body mass. The single dose of the inventive medicinal preparation for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and organs comprises 20 000-500 000 Kunz units of the DNAse ferment. The oral administration of the above-mentioned important doses of the preparation only allows the catalytically significant amount of DNAse to be absorbed into the systemic circulation in such a way that the dose-dependent treating effect thereof is exhibited.03-11-2010
20100086534STABILIZATION OF PERHYDROLASES - Disclosed herein are enzyme powders comprising a spray-dried formulation of at least one CE-7 esterase, at least one oligosaccharide excipient, and optionally at least one surfactant. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned enzyme powders. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided.04-08-2010
20120058102PHARMACOLOGICALLY INDUCED TRANSGENE ABLATION SYSTEM - The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as “PITA” (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript.03-08-2012
20120207739TREATMENT OF PRE-TERM NEONATES - This invention relates to the treatment of pre-term neonates with paraoxonase 3 (PON3) or serum amyloid A like protein 3 (SAA3) to reduce or prevent the morbidity and mortality associated with prematurity.08-16-2012
20120064057NOVEL ADAMTS-13 MUTANT - The present invention provides a method of enhancing an enzymatic activity of ADAMTS-13 and/or a method of reducing reactivity to an anti-ADAMTS-13 neutralizing antibody as well as a mutant of ADAMTS-13 prepared by the methods. The method of the present invention is characterized by substituting at least one charged amino acid in a disintegrin-like domain, a cysteine-rich domain or a spacer domain of ADAMTS-13 other than the following amino acids with a different amino acid: arginine at position 326, aspartic acid at position 330, aspartic acid at position 343 and arginine at position 349 in the disintegrin-like domain, aspartic acid at position 480, arginine at position 488, arginine at position 498, arginine at position 507, aspartic acid at position 533 and aspartic acid at position 543 in the cysteine-rich domain, and glutamic acid at position 641 and arginine at position 660 in the spacer domain. The present invention also provides a therapeutic agent for thrombotic disease comprising as an active ingredient the mutant of ADAMTS-13 prepared by the method.03-15-2012
20090162337EMBEDDED ENZYMES IN POLYMERS TO REGULATE THEIR DEGRADATION RATE - A biodegradable material, capable of carrying a bioactive agent, comprising a polymer matrix and an enzyme capable of degrading the polymer matrix to enable the release of the bioactive agent.06-25-2009
20090324575LYSOSOMAL PHOSPHOLIPASE A2 (LPLA2) ACTIVITY AS A DIAGNOSTIC AND THERAPEUTIC TARGET FOR IDENTIFYING AND TREATING SYSTEMIC LUPUS ERYTHEMATOSIS - The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.12-31-2009
20120207738Pretreatment of Post Exposure Treatment for Exposure to a Toxic Substance by Pulmonary Delivery (Inhaler) of a Bioscavenger - The present invention relates to a treatment by pulmonary delivery of a bioscavenger to animals as an effective antidote to prevent toxicity produced by exposure of an animal to nerve agents and other toxic substances.08-16-2012
20100203031METHOD FOR ENHANCING THE CLEAVAGE ACTIVITY OF I-CREI DERIVED MEGANUCLEASES - A method for enhancing the cleavage activity of an I-CreI derived meganuclease, comprising the site-specific mutation of at least one amino acid residue which is selected in the group consisting of: the glycine at position 19, the phenylalanine at position 54, the phenylalanine at position 87, the serine at position 79, the valine at position 105 and the isoleucine at position 132 of I-CreI, and its application for the manufacturing of meganuclease cleaving a DNA target of interest, for use in genome therapy (treatment of genetic diseases) and genome engineering (making of transgenic animals, transgenic plants and recombinant cell lines).08-12-2010
20110091439COSMETIC USE OF ACID CERAMIDASE TYPE PROTEINS - A method for preventing and/or treating the signs of skin aging comprises administering as an agent into an individual in need thereof an effective amount of acid ceramidase, polypeptides derived from this protein or analogues thereof, a nucleic sequence encoding such a polypeptide, or an agent for modulating the expression or the biological or biochemical activity of such a polypeptide. A methods for characterizing a state of an epithelium comprises determining a content of acid ceramidase, polypeptides derived from this protein or analogues thereof, or a nucleic sequence encoding such a polypeptide in an epidermis sample.04-21-2011
20090202511Targeted protein replacement for the treatment of lysosomal storage disorders - The present invention relates to compositions and methods for delivering lysosomal proteins. The compositions and methods described herein permit the targeted delivery of exogenous lysosomal proteins to cell surface proteins that allow their internalization via non-clathrin pathways. The present invention further relates to the use 10 of the compositions and methods for enzyme replacement therapy of lysosomal storage diseases. Nucleic acids, recombinant cells and kits useful for making and using the compositions of the invention are also provided.08-13-2009
20110091440Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases - A composition and method for the treatment of Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, amyloidosis and amyotrophic lateral sclerosis, as well as neuro-degenerative diseases and protein aggregation diseases, includes an effective amount of a compound selected from the group consisting of phytic acid (inositol hexakisphosphate), a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams per day, with or without a dephosphorylating enzyme.04-21-2011
20120121571Lysosomal Phospholipase A2 (LPLA2) Activity as a Diagnostic and Therapeutic Target for Identifying and treating Systemic Lupus Erythematosis - The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.05-17-2012
20120121570Test for Predicting Neutralization of Asparaginase Activity - Method of in vitro measurement of the presence of factors that are able to neutralize asparaginase activity in a sample of blood, plasma, serum or derived medium that may contain asparaginase neutralizing factors, obtained from a patient, comprising mixing of said sample with asparaginase, incubation of said mixture, then measurement of the residual asparaginase activity in the mixture and determination or quantification of the presence of said neutralizing factors. Method for predicting the efficacy of a treatment with asparaginase.05-17-2012
20120121569METHODS OF TREATING INFECTIONS ORIGINATING FROM VIRUSES IN THE HERPESVIRIDAE FAMILY - Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.05-17-2012
20120164126PROTEINS FOR USE IN HUMAN AND ANIMAL STAPHYOCOCCUS INFECTIONS - The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO:1 as well as variants of this polypeptide. Furthermore, the present invention relates to nucleic acids and vectors encoding for said polypeptide and variants thereof as well as host cells comprising these nucleic acids and/or vectors. Finally, the present invention relates to the uses of said polypeptide, variants thereof, nucleic acid sequences, vectors and host cells, in particular for the treatment or prophylaxis of a subject infected by or exposed to Staphylococci.06-28-2012
20100247508SITE-DIRECTED PEGYLATION OF ARGINASES AND THE USE THEREOF AS ANTI-CANCER AND ANTI-VIRAL AGENTS - Mono-pegylated arginase conjugate and method producing thereof. The mono-pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method of producing such arginase conjugate has a main step of genetically modifying the gene encoding an arginase so that the PEG moiety can attach to the enzyme at a predetermined, specific intended site. This is achieved by removing the PEG attaching amino acid residues at undesirable sites while keeping (or adding, if necessary) the one at the desirable site of the enzyme. Two exemplary mono-pegylated arginase conjugates so produced are human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys09-30-2010
20120128651ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) BIOMARKERS - The present invention concerns the use of biomarkers for acute lymphoblastic leukemia (ALL) to prognose or evaluate a patient with ALL who is Ph+. Methods and compositions are provided that concern these ALL biomarkers. In specific embodiments, methods for determining whether an ALL patient should be treated with standard chemotherapy are provided.05-24-2012
20120134979METHODS AND COMPOSITIONS FOR THE TREATMENT OF SICKLE CELL DISEASE - Presented are mechanism based compositions and methods for treatment of SCD and SCD associated symptoms and disorders, particularly increased RBC sickling, HbS polymerization, hemolysis, tissue congestion and disruption and organ damage or failure in a mammal. The disclosed methods feature the identification of the heretofore unknown role of adenosine levels and signaling in the development of SCD and SCD associated symptoms and disorders. This discovery has lead to the identification of compositions for use as therapies for SCD and SCD associated disorders and symptoms in a mammal.05-31-2012
20120230972Salinosporamides and Methods for Use Thereof - The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet 09-13-2012
20100015122CLONING OF HONEY BEE ALLERGEN - The present invention relates to a recombinant polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee allergen Api m3 (acid phosphatase). The invention further relates to nucleic acid encoding the polypeptide, expression vectors, host cells and methods of preparing the polypeptide, as well as diagnostic and pharmaceutical uses thereof.01-21-2010
20120171191MEGANUCLEASE VARIANTS CLEAVING THE GENOME OF A PATHOGENIC NON-INTEGRATING VIRUS AND USES THEREOF - An I-CreI variant, wherein at least one of the two 1-Cre1 monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the genome of a non-integrating virus, in particular herpes simplex virus (HSV) or Hepatitis B virus (HBV) for use in genome engineering and for in vivo and ex vivo (gene cell therapy) genome therapy as well as the treatment of a virus infection.07-05-2012
20080213241PROTEASE COMPOSITION AND METHOD FOR TREATING A DIGESTIVE DISORDER - There is provided methods, kits, combinations, and compositions comprising protease enzymes and a lipase enzyme for treating a digestive disorder in a subject in need thereof. The methods, kits, combinations, and compositions may also be used along with an agent (or combination of agents) for raising the gastric pH, a digestive enzyme useful in enhancing digestive activity, a dietary supplement, or a pharmaceutical agent.09-04-2008
20120177628ARGINASE FORMULATIONS AND METHODS - Methods and composition for generation of arginase variants with high serum persistence are provided. For example, in certain aspects methods for purifying pegylated arginase are described. Furthermore, the invention provides stabilized arginase multimers or pharmaceutical composition thereof.07-12-2012
20100272703IRON FORTIFICATION MUTRITIONAL BLEND - Nutritional blend suitable for fortifying food containing 0.5 mg to 10 mg iron in form of a bioavailable iron source and 50 FTU to 5000 FTU phytase, each per 1 g of the nutritional blend and its use.10-28-2010
20100284992Phospholipase C and Method of Use - The present invention provides a method for reducing angiogenesis using a phospholipase C.11-11-2010
20090060896Gene repair involving in vivo excision of targeting DNA - Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.03-05-2009
20120225048Novel Cellular Factor-Containing Solution Compositions - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.09-06-2012
20110123515EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASES - The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.05-26-2011
20110123514ANGIOGENIN-ENRICHED MILK FRACTIONS - The invention provides methods for enriching a milk extract for angiogenin, such methods involving separation by size, charge or immunoaffinity. The invention also provides the angiogenin enriched extract produced by the methods and provides them in pharmaceutical and neutraceutical compositions and foods for treating a variety of diseases or disorders that can be treated by angiogenin.05-26-2011
20110123512METHOD OF REGULATING THE HEAT SHOCK RESPONSE - The present invention is directed to method of modulating a heat shock response in a first cell of a multicellular organism comprising stimulating or inhibiting an HSR signaling activity of a second cell, wherein the second cell is a neuronal cell that regulates heat shock response activation in the first cell and that does not directly innervate the first cell.05-26-2011
20120148561USE OF RUNX3 AND MIR-532-5P AS CANCER MARKERS AND THERAPEUTIC TARGETS - The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts.06-14-2012
20120230971CHROMOSOMAL MODIFICATION INVOLVING THE INDUCTION OF DOUBLE-STRANDED DNA CLEAVAGE AND HOMOLOGOUS RECOMBINATION AT THE CLEAVAGE SITE - Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.09-13-2012
20080299107COMBINATIONS OF HUMAN PROTEINS TO ENHANCE VIABILITY OF TRANSPLANTED STEM CELLS AND PROGENITOR CELLS - Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human α12-04-2008
20080299105Inhibition of Feline Calicivirus - We conducted feline calicivirus (FCV) inhibition experiment with two anti-viral aminohydrolases, asparaginase and glutaminase. We found that in the presence of 8 units and 4 units/ml of asparaginase, about 90% of FCV replication was inhibited. In contrast, glutaminase showed no significant inhibition effect on the virus replication. We have also shown that asparaginase did not inhibit the replication of adenovirus suggesting that the inhibition was specific. Our results implicated that asparaginase could be used as a candidate for anti-FCV drug development.12-04-2008
20110002907Methods, Systems, Compositions And Dosage Forms For Diagnosing And Treating Male Infertility - Methods and systems are provided for diagnosing male infertility relating to inadequate production of phosphatidic acid and are complementary to the routine tests, assessing sperm count, motility, viability, head morphology, and white blood cell count. Additional therapeutic methods, compositions and dosage forms are provided for treating male infertility that is related to inadequate production of phosphatidic acid. Such therapeutic approaches involve the use of phosphatidic acid or at least one of its precursors in the sperm intracellular signaling pathway.01-06-2011
20120328596USE OF PLATELET ACTIVATING FACTOR ACETYLHYDROLASE AS A BIOMARKER FOR ANAPHYLAXIS - The invention provides a use of platelet activating factor acetylhydrolase (PAF-AH) activity as a biomarker for severe or fatal anaphylaxis in a subject. The level of PAF-AH activity inversely correlates with the susceptibility to severe or fatal anaphylaxis. The use comprises assaying PAF-AH activity in a sample from the subject and comparing the measured activity to a reference value, wherein a lower level of measured PAF-AH activity relative to said reference level of PAF-AH activity indicates a presence of or susceptibility to severe or fatal anaphylaxis in the subject. A method for treating or preventing severe or fatal anaphylaxis in a subject is also provided. The method comprises increasing serum platelet activating factor acetylhydrolase (PAF-AH) concentration in the subject by administering to the subject, PAF-AH and/or a PAF receptor antagonist. A composition for treating severe or fatal anaphylaxis is also provided.12-27-2012
20130183283Method for Treating Systemic DNA Mutation Disease - The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.07-18-2013
20120321610METHOD TO INHIBIT NEUROPATHIC PAIN BY INTRATHECAL INJECTION OF PROTEIN PHOSPHATASES - A method and corresponding pharmaceutical composition to inhibit neuropathic pain by injecting intrathecally into a mammalian subject a neuropathic pain-inhibiting amount of a phosphatase falling within E.C. 3.1.3.x, more specifically a protein phosphatase falling within E.C. 3.1.3.16, and most specifically calcineurin.12-20-2012
20120321609METHOD OF TREATING PSYCHOLOGICAL DISORDERS - A method of desensitizing 5-HT12-20-2012
20120282238Use of Secreted Phospholipases A2 in the Diagnosis and Treatment of Malaria - The present invention relates to an in vitro method of diagnosis of a 11-08-2012
20100215635SMALL MOLECULES TO INDUCE WEIGHT LOSS OR TO REDUCE WEIGHT GAIN - Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds alone or in combination with alkaline phosphatase or other weight loss-inducing drugs or methods to reduce or reverse excess weight gain and obesity as well as reduce the risk of development and help treatment of diseases and unhealthy conditions related to overweight and obesity.08-26-2010
20120100128METHODS OF AND COMPOSITIONS FOR INHIBITING THE PROLIFERATION OF MAMMALIAN CELLS - A method of preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The method is effected by administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family having actin binding activity.04-26-2012
20120100127Method to Increase the Absorption of Unsaturated Fatty Acids by Human Infants - The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant.04-26-2012
20120100126Method to Increase the Growth Velocity of Human Infants - The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds. In another aspect, the present invention relates to methods to: (X) protect the small bowel mucosa of a human infant from damage; to (Y) protect an immature intestinal epithelium of a human infant from the deleterious effects of incompletely digested and/or excess fat and/or lipid; and/or to (Z) limit accumulation of incompletely digested and/or excess fat and/or lipid in the ileum of a human infant; said methods in each case comprising the step of enteral administration of rhBSSL.04-26-2012
20130011380Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming - Methods, compositions and kits for modulating demethylation in a mammalian cell are provided. Also provided are methods, compositions and kits for screening candidate agents for activity in modulating genomic DNA demethylation in mammalian cells. These methods, compositions and kits find use in producing induced pluripotent stem cells (iPS) and somatic cells in vitro and for treating human disorders including cancer and disorders arising from defects in genomic imprinting.01-10-2013
20130017185Thermostable Phytase VariantsAANM De Maria; LeonardoAACI FrederiksbergAACO DKAAGP De Maria; Leonardo Frederiksberg DKAANM Skov; Lars KobberoeeAACI BagsvaerdAACO DKAAGP Skov; Lars Kobberoee Bagsvaerd DKAANM Skjoet; MichaelAACI RoskildeAACO DKAAGP Skjoet; Michael Roskilde DK - The present invention relates to a phytase which has at least 70% identity to a phytase derived from 01-17-2013
20110158975USE OF RUNX3 AND MIR-532-5P AS CANCER MARKERS AND THERAPEUTIC TARGETS - The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts.06-30-2011
20110158974Heterodimeric Meganucleases and Use Thereof - Heterodimeric meganuclease comprising two domains of different meganucleases which are in two separate polypeptides, said heterodimeric meganuclease being able to cleave a chimeric DNA target sequence comprising one different half of each parent meganuclease DNA target sequence.06-30-2011
20130022591Methods of Reducing or Inhibiting Toxic Effects Associated with a Bacterial Infection Using Alkaline Phosphatase - This invention relates generally to a therapeutic use of alkaline phosphatase to reduce or inhibit toxic effects associated with a bacterial infection in a subject.01-24-2013
20130022590Compositions Comprising Zinc Finger Domains and Uses Therefor - The present invention relates to compositions of matter comprising zinc finger domains that bind to single-stranded RNA and are useful for modifying gene expression such as by regulating processing of messenger RNA (mRNA) or non-coding RNA (ncRNA). The invention also relates to screening, diagnostic and therapeutic methods employing such compositions of matter.01-24-2013
20130022589METHODS OF TREATING HUMAN PAPILLOMAVIRUS - Two RNases (ranpirnase and the second embodiment disclosed in U.S. Pat. No. 5,728,805) are tested against human papillomavirus infections. QRT-PCR assays indicate that the RNases have anti-viral activity against type 11 HPV.01-24-2013
20080254018IMMOBILIZED ANGIOGENIN MIXTURES AND USES THEREOF - Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by covalent immobilization on a naturally occurring substrate, such as a polysaccharide substrate, are disclosed. In particular, the polysaccharide substrate includes galactose-rich polysaccharide.10-16-2008
20080248018PHARMACEUTICAL PREPARATION AND METHOD OF TREATMENT OF HUMAN MALIGNANCIES WITH ARGININE DEPRIVATION - The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.10-09-2008
20080241120Use of Pilocarpine For Hypoptyalism Treatment - The object of the invention is a composition for the treatment of hypoptyalism, characterized in that it comprises pilocarpine combined with at least one bioadhesive polymer so as to allow dissolution and local attachment to the tissues of the buccopharyngeal cavity.10-02-2008
20080226617Pharmaceutical Preparation and Method of Treatment of Human Malignancies with Arginine Deprivation - The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition.09-18-2008
20110262422ORALLY ADMINISTRABLE DOSAGE FORMS COMPRISING ANGIOGENIN AND USES THEREOF - The invention provides a method of treatment of any disorder in which administration of angiogenin is beneficial wherein the angiogenin is administered orally. Particularly, the oral angiogenin does not require a carrier or excipient or for the protein to be encapsulated or subjected to any other mechanism to improve its oral bioavailability.10-27-2011
20130171125Methods for the Regulation of Cellular Metabolism Through the Modulation of SIRT3 Activity - The present invention relates to methods of preventing or treating cancer and/or decreasing damage to organs or tissues exposed to hypoxic conditions through the use of agents that modulate the expression or activity of SIRT3.07-04-2013
20130171124Compositions And Methods Of Treating Head And Neck Cancer - The present invention provides methods related to the treatment of head and neck squamous cell carcinoma (HNSCC) and its associated premalignant lesions. In particular, the invention features methods which may specifically target HNSCC-associated genes and alter gene expression to treat or alleviate a symptom of HNSCC, or its related premalignant lesions. These methods may involve decreasing the function of an HNSCC-associated gene with aberrant gain-of-function; or increasing the function of an HNSCC-associated gene with aberrant loss-of-function.07-04-2013
20130129707ANTIMICROBIAL ACTIVITY ENHANCING AGENT - An antimicrobial activity enhancing agent for lactoferrin or a lactoferrin hydrolysate, which contains a milk protein as an active ingredient and has the following properties, and a method for producing the antimicrobial activity enhancing agent, which comprises (a) the step of contacting raw milk with a cation exchange resin to adsorb proteins in the raw milk to the cation exchange resin, (b) the step of washing the cation exchange resin having undergone the adsorption treatment, and flowing an elution solvent to elute a protein fraction having an isoelectric point of 9.0 to 11.0, and (c) the step of subjecting the eluted protein fraction to membrane filtration using an ultrafiltration membrane having a molecular weight cutoff of 30 kDa to prepare the milk protein having the following properties:05-23-2013
20110268720FORMULATIONS OF 5-FLUOROCYTOSINE AND USES THEREOF - The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.11-03-2011
20130095091METHODS OF REGULATING UPTAKE AND TRANSCELLULAR TRANSPORT OF LEUKOCYTES AND THERAPEUTICS - Methods for controlling and regulating engulfment, uptake and/or transcellular transport at a stage following initial engagement of an agent to the endothelium are provided, based on the identification of CAM-mediated endocytosis and the sphingomyelin/ceramide pathway as active steps in transcellular TEM. Administration of regulators relating to the identified pathways, such as NHE1, sphingomyelinases, acid sphingomyelinase and ceramide, permit control and regulation of uptake and transcellular transport. Control and regulation of uptake and/or transcellular transport is applicable in strategies to modulate inflammation, provide controlled and/or targeted delivery of agents, control pathogenic invasion, recover action of an inhibited CAM-mediated uptake or transendothelial pathway, or provide uptake or transendothelial transport by targeting cell surface markers other than ICAM-1.04-18-2013
20130101573DEGRADATION RESISTANT HSP70 FORMULATIONS AND USES THEREOF - The present invention relates to novel therapies that utilize stabilized exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of degradation resistant formulations of HSP70. Furthermore, the present invention is directed to methods comprising the administration of stabilized exogenous HSP70 for use in the treatment of HSP70 related disorders or conditions, for example, for increased endurance or alleviating fatigue syndrome04-25-2013
20130101574METHODS OF USING THROMBIN PEPTIDE DERIVATIVES - The present invention provides methods of reducing mortality in a subject exposed to a lethal dose of radiation, methods of reducing the risk of developing bacterial, fungal or viral systemic infection in a subject who is exposed or not exposed to radiation, methods of prevention and treatment of oral complications, particularly oral complications as a result of treatment with chemotherapy or radiation therapy, methods of treating dermal ulcers, particularly diabetic dermal ulcers, pressure dermal ulcers, venous stasis ulcers, and arterial ulcers, methods of promoting bone growth, and methods of promoting cartilage growth and repair in a subject in need thereof, by administering a thrombin peptide derivative to a subject. The administration may be local or systemic.04-25-2013
20130121985METHOD AND PHARMACOLOGICAL COMPOSITION FOR THE DIAGNOSIS AND TREATMENT OF MALE SUB-FERTILITY - Methods for treating male sub-fertility by administering a pharmaceutical composition to a subject in need thereof are provided. The pharmaceutical compositions include an agent that causes a reduction in an effect of extracellular DNA on sperm cells. The agent may be, for example, an enzyme that degrades DNA such as DNase, a substance that blocks the interaction between cell free DNA and sperm cell surface receptors, a substance that binds to DNA, a substance that inhibits endogenous sperm cell DNase, a substance that inhibits a member of a signal transduction pathway mediated by DNA binding to sperm cell surface receptors, or an agent that stimulates production of an endogenous substance that causes a reduction in an antifertility effect of cell free DNA on sperm cells.05-16-2013
20130129706Crotoxin Administration for Cancer Treatment and Pain Relief - Disclosed is a method for treating cancer and/or pain using an intra-patient dose escalation procedure to deliver dosages of crotoxin.05-23-2013
20080199450ACID CERAMIDASE AND CELL SURVIVAL - The present invention relates to methods of promoting the survival of cells by treating the cells with acid ceramidase. A kit for promoting ex vivo cell survival is also disclosed, as is a method of predicting in vitro fertilization outcome of a female subject.08-21-2008
20120276077THERAPEUTIC RIBONUCLEASES - The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.11-01-2012
20120276076ARF6 AS A NEW TARGET FOR TREATING ALZHEIMER'S DISEASE - The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to ARF6 and/or ARF6 effector proteins as new targets in Alzheimer's disease, and based thereon, screening methods for compounds that reduce amyloid beta peptide formation in mammalian cells by affecting ARF6-mediated endosomal sorting.11-01-2012
20130156749Pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger - The present invention relates to a treatment by pulmonary delivery of a bioscavenger to animals as an effective antidote to prevent toxicity produced by exposure of an animal to nerve agents and other toxic substances.06-20-2013
20130183282Meganuclease variants cleaving a DNA target sequence from the rhodopsin gene and uses thereof - The invention relates to meganuclease variants which cleave a DNA target sequence from the human Rhodopsin gene (RHO), to vectors encoding such variants, to a cell, an animal or a plant modified by such vectors and to the use of these meganuclease variants and products derived therefrom for genome therapy, ex vivo (gene cell therapy) and genome engineering including therapeutic applications and cell line engineering.07-18-2013
20110293594REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE - The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.12-01-2011
20110311508METHOD OF MODULATING HSF-1 - The present invention is directed to methods of modulating HSF1 activity comprising modifying the acetylation of the DNA binding domain of the HSF1.12-22-2011
20110311507Methods for Diagnosing and Treating Autoimmune Disorders - Provided herein are, inter alia, methods of identifying patients who are at risk of developing an autoimmune disorder, and treating patients suffering from autoimmune disorders.12-22-2011
20090208479Compositions and Methods for Effecting the Levels of High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein AI, Very Low Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol - Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme.08-20-2009
20120039861IDENTIFICATION OF EXTRACELLULAR FORM OF PTEN THAT CAN BE USED TO TREAT TUMORS - An isolated human phosphatase and tensin homolog long polypeptide (PTEN-long) comprising SEQ ID NO:1, fragments and analogues thereof, nucleic acids encoding such and compositions comprising such are provided. Methods to inhibit angiogenesis in a solid tumor, treat a solid tumor, and inhibit growth of a solid tumor using PTEN-long, fragments and analogues thereof, are provided.02-16-2012
20130202578COMPOSITIONS AND METHODS FOR SELECTIVELY PRODUCING SIRNA - The disclosure provided herein provides compositions and methods for producing siRNA. Also disclosed are compositions and methods for modulating the production of siRNA. Also disclosed herein are compositions and methods of treating a disease in a subject comprising administering a Dicer enzyme comprising a helicase domain or a mutated Dicer enzyme to a subject. Also disclosed herein are methods of screening for a candidate modulator that modulates siRNA production.08-08-2013
20130202579USE OF CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE-ALPHA (CCT-ALPHA) AS A BIOMARKER FOR CANCER PROGNOSIS - It has previously been demonstrated that positive 8F1 immunohistochemistry is an indicator of a poor cancer prognosis and poor response to chemotherapy. The 8F1 antibody was generated by immunization against ERCC1, a DNA repair protein, but recognizes a second, previously unidentified protein in cells and tissues. Disclosed herein is the finding that in addition to ERCC1, the 8F1 antibody recognizes the choline phosphate cytidylyltransferase-α (CCTα) protein. Thus, provided herein is a method of determining the prognosis of a patient with cancer by specifically detecting expression of CCTα in a sample obtained from the subject. Also provided is a method of predicting the response of a cancer patient to treatment with a genotoxic therapy by specifically detecting expression of CCTα in a sample obtained from the subject.08-08-2013
20130202580Use Of 2,5-Dihydroxybenzene Derivatives For Treating Actinic Keratosis - The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.08-08-2013
20130202577DIAGNOSTIC AND PROGNOSTIC ASSAY FOR BREAST CANCER - The invention relates to the finding that T cell protein tyrosine phosphatase (TCPTP) has a tumour suppressor function. In one particular application, the invention provides a method of diagnosis and/or prognosis of cancer in a subject involving the assessment, in a suitable body sample, of any lack or reduction of TCPTP protein and/or Ptpn2 gene expression. The invention also provides a method of treating or preventing cancer in a subject involving administering to a subject an agent for modulating the activity of TCPTP.08-08-2013
20100034799ANTI-COCAINE COMPOSITIONS AND TREATMENT - Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.02-11-2010
20120082656COMPOSITION COMPRISING THE PURIFIED EXTRACT OF BEE VENOM FOR PREVENTING AND TREATING DEGENERATIVE BRAIN DISEASE - The present invention relates to a composition comprising the purified extract of bee venom for preventing and treating degenerative brain diseases and the use thereby. The purified extract of bee venom shows potent inhibitory effect on microglial cell activation and abnormal circling behavior using by animal model of degenerative brain disease as well as potent cell-protective activity therefore, it can be useful in treating and preventing the degenerative brain disease as a medicament.04-05-2012
20130209439INHIBITORS OF PDE4 BINDING TO HSP20 - The present invention provides methods and materials for use in increasing HSP20 activation in a biological system, for example by increasing phosphorylation of Ser16 of HSP20. In one aspect, the invention provides a method for increasing HSP20 activation in a biological system, comprising contacting the system with an antagonist capable of inhibiting PDE4 binding to HSP20, the antagonist comprising or consisting essentially of a fragment of PDE4 or an analogue thereof. In a further aspect the invention provides a method of screening for an agent able to increase activation of HSP20. A preferred antagonist has a C-terminal lysine residue.08-15-2013
20130209438Prostatic Acid Phosphatase for the Treatment of Pain - Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord.08-15-2013
20130209436LYSOSOMAL STORAGE DISEASE ENZYMES - The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.08-15-2013
20130209437I-CREI HOMING ENDONUCLEASE VARIANTS HAVING NOVEL CLEAVAGE SPECIFICITY AND USE THEREOF - A method for engineering I-CreI homing endonuclease variants able to cleave mutant I-CreI sites having variation in positions ±8 to ±10. A I-CreI homing endonuclease variant obtainable by said method, a vector encoding said variant, a cell, an animal or a plant modified by said vector. Use of said I-CreI endonuclease variant and derived products for genetic engineering, genome therapy and antiviral therapy.08-15-2013
20130209440METHODS AND COMPOSITIONS FOR THE TREATMENT OF INSULIN-ASSOCIATED MEDICAL CONDITIONS - A method of increasing insulin content in a pancreatic beta cell is disclosed. The method comprising expressing in the pancreatic beta cell an exogenous polynucleotide encoding at least one microRNA or a precursor thereof, wherein the microRNA is selected from the group consisting of miR-15, miR-16, miR-24, miR-26, miR-27, miR-29, miR-30, miR-129, miR-141, miR-148, miR-182, miR-200, miR-376 and Let-7, thereby increasing the insulin content in the pancreatic beta cell.08-15-2013

Patent applications in class Hydrolases (3. ) (e.g., urease, lipase, asparaginase, muramidase, etc.)

Patent applications in all subclasses Hydrolases (3. ) (e.g., urease, lipase, asparaginase, muramidase, etc.)